Multiple Myeloma Clinical Trials

A listing of 180 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 180 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

NCT01408225

Recruiting

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they li... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/27/2025

Locations: Ohio State University Medical Center, Columbus, Ohio

Conditions: Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma

Learn More ›

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653

Recruiting

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * To assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity. * To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. * To determine pharma... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/11/2023

Locations: Gabrail Cancer & Research Center, Canton, Ohio

Conditions: Multiple Myeloma

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

ALL

Ages:

2 months and above

Trial Updated:

05/30/2025

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416

Recruiting

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be app... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: Banner Gateway Medical Center, Gilbert, Arizona +223 locations

Banner Gateway Medical Center, Gilbert, Arizona

Banner MD Anderson Cancer Center, Gilbert, Arizona

Ronald Reagan UCLA Medical Center, Los Angeles, California

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California

UCLA Hematology/Oncology - Santa Monica, Los Angeles, California

Georgetown University Medical Center, Washington, District of Columbia

Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

Emory University Hospital Midtown, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Investigational Drug Service, Emory University Clinic, Atlanta, Georgia

Winship Cancer Institute, Emory University, Atlanta, Georgia

Loyola University Chicago, Maywood, Illinois

Ascentist Doctor Hospital, Leawood, Kansas

American Oncology Partners, P.A. dba MidAmerica Cancer Care, LLC, Merriam, Kansas

O'Brien Pharmacy, Mission, Kansas

University of Michigan, Ann Arbor, Michigan

University Of Mississippi Medical Center, Jackson, Mississippi

University of Mississippi Medical Center, Jackson, Mississippi

American Oncology Partners, P.A. dba MidAmerica Cancer Care, Kansas City, Missouri

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

WMCHealth Advanced Physician Services, Hawthorne, New York

Westchester Medical Center, Valhalla, New York

Cleveland Clinic, Cleveland, Ohio

OhioHealth Arthur G.H. Bing, MD, Cancer Center, Columbus, Ohio

OhioHealth Research Institute, Columbus, Ohio

OhioHealth Riverside Methodist Hospital, Columbus, Ohio

Baylor University Medical Center, Dallas, Texas

Baylor Scott & White Medical Center - Temple, Temple, Texas

Royal Prince Alfred Hospital, Camperdown, New South Wales

Shoalhaven District Memorial Hospital, Nowra, New South Wales

Westmead Hospital, Westmead, New South Wales

Wollongong Hospital, Wollongong, New South Wales

Pindara Private Hospital, Benowa, Queensland

QScan Radiology Clinics, Clayfield, Queensland

Princess Alexandra Hospital, Woolloongabba, Queensland

Epworth Healthcare, East Melbourne, Victoria

Precision Haematology, East Melbourne, Victoria

St Vincent's Hospital (Melbourne), Fitzroy, Victoria

Slade Pharmacy, Richmond, Not set

Medizinische Universität Wien, Vienna, Wien

Hanusch-Krankenhaus, Vienna, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Bruxelles-capitale, Région DE

Grand Hôpital de Charleroi, Charleroi, Hainaut

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi, Yvoir, Namur

UZ Gent, Gent, Oost-vlaanderen

ZNA Middelheim, Antwerpen, Not set

Zna Cadix, Antwerpen, Not set

UZ Brussel, Brussel, Not set

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Bahia

Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, RIO Grande DO SUL

Centro de Pesquisa Clínica - Área Administrativa, Porto Alegre, RIO Grande DO SUL

Hospital Mae de Deus, Porto Alegre, RIO Grande DO SUL

Hospital Amaral Carvalho, Jaú, SÃO Paulo

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP), Ribeirão Preto, SÃO Paulo

BP - A Beneficencia Portuguesa de São Paulo, Sao Paulo, SÃO Paulo

Clínica Médica São Germano LTDA, SP, SÃO Paulo

Fundação Doutor Amaral Carvalho, Jaú, Not set

Américas Medical City, Rio de Janeiro, Not set

Instituto de Educação, Pesquisa e Gestão em Saúde, Rio de Janeiro, Not set

ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis, São Paulo, Not set

HU UNIFESP / SPDM - Hospital São Paulo, São Paulo, Not set

Universidade Federal de Sao Paulo, São Paulo, Not set

Hospital Japonês Santa Cruz, São Paulo, Not set

Clínica Médica São Germano S/S Ltda, São Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta

Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick

Saint John Regional Hospital, Saint John, New Brunswick

Hamilton Health Sciences Corporation, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Windsor Regional Hospital Cancer Program, Windsor, Ontario

Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal,, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ, Montreal, Quebec

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Institute of hematology&blood disease hospital, Tianjin, Tianjin

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang

Fakultní nemocnice Brno Bohunice, Brno, Brno-město

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Hradec Králové

Fakultni nemocnice Ostrava, Ostrava, Moravskoslezský KRAJ

Fakultni nemocnice Olomouc, Olomouc, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Oulun yliopistollinen sairaala, Oulu, Pohjois-pohjanmaa

Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus), Helsinki, Uusimaa

Turku University Hospital, Turku, Varsinais-suomi

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Haute-garonne

Pitie Salpetriere University Hospital, Paris, Orne

Gustave Roussy, Villejuif, Val-de-marne

Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne

Chu Grenoble Alpes, La Tronche, Not set

Hopital Claude Huriez - CHU de Lille, Lille, Not set

Hôpital Saint Antoine, Paris Cedex 12, Not set

Hopital Lyon Sud, Pierre Benite, Not set

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau, Tours, Not set

Universitätsklinikum Würzburg, Würzburg, Bayern

Universitätsmedizin Johannes Gutenberg Universität Mainz, Mainz, Rheinland-pfalz

Universitätsklinikum Leipzig, Leipzig, Sachsen

Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-holstein

Charite Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Not set

Klinikum Chemnitz gGMbH, Chemnitz, Not set

Universitätsklinikum Essen, Essen, Not set

Klinikum rechts der Isar der Technischen Universität München, München, Not set

Alexandra General Hospital of Athens, Athens, Attikí

Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Kentrikí Makedonía

University Hospital of Ioannina, Ioannina, Ípeiros

Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Somogy

Semmelweis University, Budapest, Not set

Dél-Pesti Centrumkórház, Budapest, Not set

Debreceni Egyetem Klinikai Kozpont, Debrecen, Not set

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház, Nyíregyháza, Not set

Artemis hospital, Gurugram, Haryana

Medanta-The Medicity, Gurugram, Haryana

Fortis Memorial Research Institute, Gurugram, Haryana

Himalayan Institute Hospital Trust University, Dehradun, Uttarakhand

Tata Medical Center, Kolkata, WEST Bengal

Rajiv Gandhi Cancer Institute And Research Centre, Delhi, Not set

Soroka Medical Center, Be'er Sheva, Hadarom

Rabin Medical Center, Petah-Tikva, Hamerkaz

Sheba Medical Center, Ramat Gan, Hamerkaz

Rambam Health Care Campus, Haifa, Hatsafon

Tel-Aviv Sourasky Medical Center Dana-Dwek Children's Hospital, Tel Aviv, Tell Abīb

Shaare Zedek Medical Center, Jerusalem, Yerushalayim

Hadassah Medical Center, Jerusalem, Yerushalayim

Hadassah Mount Scopus Medical Center, Jerusalem, Yerushalayim

Shaare Zedek Medical Center, Jerusalem, Not set

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Emilia-romagna

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia

Policlinico "G. Rodolico", Catania, Sicilia

Azienda Ospedaliero Universitaria Senese, Siena, Toscana

Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

AOU Policlinico Umberto I, Roma, Not set

Nagoya City University Hospital, Nagoya, Aichi

Gunma University Hospital, Maebashi, Gunma

Kobe City Medical Center General Hospital, Kobe-city, Hyogo

Iwate Medical University Hospital, Yahaba-cho, Iwate

University Hospital,Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto

Tohoku University Hospital, Sendai, Miyagi

Hamamatsu University Hospital, Hamamatsu-shi, Shizuoka

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Nippon Medical School Hospital, Bunkyo-ku, Tokyo

Kagoshima University Hospital, Kagoshima, Not set

National Hospital Organization Kumamoto Medical Center, Kumamoto, Not set

University Hospital,Kyoto Prefectural University of Medicine, Kyoto, Not set

National Hospital Organization Okayama Medical Center, Okayama, Not set

Osaka Metropolitan University Hospital, Osaka, Not set

Japanese Red Cross Medical Center, Tokyo, Not set

Yamagata University Hospital, Yamagata, Not set

Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [incheon]

Chonnam National University Hwasun Hospital, Hwasun Gun, Jeonranamdo

Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do

Pusan National University Hospital, Busan, Pusan-kwangyǒkshi

Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul]

Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul]

The Catholic Univ. of Korea Seoul St. Mary's Hospital(Seoul St. Mary's Hospital), Seoul, Seoul-teukbyeolsi [seoul]

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [seoul]

Kyungpook National University, Daegu, Taegu-kwangyǒkshi

Kyungpook National University Hospital, Jung-gu, Taegu-kwangyǒkshi

HagaZiekenhuis, Den Haag, Zuid-holland

Maastricht Universitair Medisch Centrum, Maastricht, Not set

Isala, Zwolle, Not set

Oslo Universitetssykehus Ullevål, Oslo, Not set

Stavanger Universitetssykehus, Stavanger, Not set

Centrum Medyczne Pratia Poznań, Skorzewo, Wielkopolskie

Uniwersyteckie Centrum Kliniczne,, Gdansk, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

Uniwersyteckie Centrum Kliniczne WUM Centralny Szpital Kliniczny, Warszawa, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Not set

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

Pratia Onkologia Katowice, Katowice, Śląskie

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruna

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [barcelona]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [barcelona]

Hospital Universitari Mutua Terrassa, Terrassa, Barcelona [barcelona]

Institut Catala d' Oncologia. Hospital Germans Trias i Pujol, Badalona, Barcelona

Hospital Universitari Mutua Terrassa, Terrassa, Barcelona

Hospital Universitario de Salamanca, Salamanca, Castilla Y LEÓN

Hospital Clínic de Barcelona, Barcelona, Catalunya [cataluña]

Clinica Universidad de Navarra, Madrid, Madrid, Comunidad DE

Hospital Universitario La Paz, Madrid, Madrid, Comunidad DE

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid

Hospital San Pedro de Alcántara, Cáceres, Not set

Institut Catala Oncologia - Hospital Universitari de Girona Dr Josep Trueta, Gerona, Not set

Hospital La Princesa, Madrid, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario HM Sanchinarro, Madrid, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitari i Politecnic La Fe, València, Not set

Helsingborgs Lasarett, Helsingborg, Skåne LÄN [se-12]

Karolinska Universitetssjukhuset Huddinge, Stockholm, Stockholms LÄN [se-01]

Södra Älvsborgs Sjukhus Borås, Borås, Västra Götalands LÄN [se-14]

Falu Lasarett, Falun, Not set

Universitetssjukhuset Örebro, Örebro, Örebro LÄN [se-18]

Universitetssjukhuset i Linköping, Linköping, Östergötlands LÄN [se-05]

CHUV (centre hospitalier universitaire vaudois), Lausanne, Vaud

UniversitätsSpital Zürich, Zürich, Zürich (DE)

Kantonsspital Baden, Baden, Not set

Inselspital Bern, Berne, Not set

Kantonsspital Winterthur, Winterthur, Not set

China Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Not set

Medipol Mega Universite Hastanesi, İstanbul, İ̇stanbul

Sisli Florence Nightingale Hastanesi, İstanbul, İ̇stanbul

Ege Universitesi Hastanesi, Izmir, İ̇zmir

Dokuz Eylul Universitesi Hastanesi, İzmir, İ̇zmir

Ankara University Health Practice and Research Hospitals, Ankara, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi, Ankara, Not set

Aydın Adnan Menderes Universitesi Hastanesi, Aydin, Not set

Erciyes Universitesi Tıp Fakultesi Hastaneleri, Kayseri, Not set

Özel Anadolu Sağlık Merkezi, Kocaeli, Not set

Addenbrooke's Hospital, Cambridge, Cambridgeshire

Queen Elizabeth Hospital Birmingham, Birmingham, England

Dewsbury and District Hospital, Dewsbury, Wakefield

Pontefract General Infirmary, Pontefract, Wakefield

Belfast City Hospital, Belfast, Not set

The Beatson West of Scotland Cancer Centre, Glasgow, Not set

Royal Berkshire Hospital, Reading, Not set

Pinderfields General Hospital, Wakefield, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226

Recruiting

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/28/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +51 locations

University of Alabama at Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles, California

UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California

Colorado Blood Cancer Institute, Denver, Colorado

Local Institution - 0062, Jacksonville, Florida

Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

University of Iowa, Iowa City, Iowa

The University of Kansas Cancer Center - Westwood, Westwood, Kansas

Norton Women's and Children's Hospital, Louisville, Kentucky

Local Institution - 0065, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University of North Carolina Medical Center, Chapel Hill, North Carolina

Local Institution - 0067, Charlotte, North Carolina

Oncology Hematology Care, Cincinnati, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

Local Institution - 0070, Philadelphia, Pennsylvania

Tennessee Oncology, Nashville, Tennessee

Local Institution - 0043, Nashville, Tennessee

Local Institution - 0069, Austin, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio, Texas

LDS Hospital, Salt Lake City, Utah

Virginia Oncology Associates, Norfolk, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

University Hospital and UW Health Clinics, Madison, Wisconsin

Local Institution - 0077, Camperdown, New South Wales

Local Institution - 0075, Brisbane, Queensland

Local Institution - 0074, Melbourne, Victoria

Local Institution - 0076, Melbourne, Victoria

Tom Baker Cancer Center, Calgary, Alberta

McGill University Health Centre, Montréal, Quebec

Nagoya City University Hospital, Nagoya, Aichi

Hyogo Medical University Hospital, Nishinomiya, Hyogo

Chiba University Hospital, Chiba, Not set

Local Institution - 0059, Kyoto, Not set

Japanese Red Cross Medical Center, Tokyo, Not set

Conditions: Multiple Myeloma

Learn More ›

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT01890486

Recruiting

To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/28/2025

Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases

Learn More ›

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449

Recruiting

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/28/2025

Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +30 locations

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Beverly Hills Cancer Center, Beverly Hills, California

Clinical Research Advisors (Encino Satellite Location), Encino, California

Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California

Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California

Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida

Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida

Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs, Florida

University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida

Sylvester Comprehensive Cancer Center - Hollywood, Hollywood, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

University of Miami Hospital And Clinics, Miami, Florida

Sylvester Comprehensive Cancer Center - Kendall, Miami, Florida

Sylvester Comprehensive Cancer Center - Plantation, Plantation, Florida

Emory University Hospital Midtown, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Winship Cancer Institute, Atlanta, Georgia

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Oncology Investigational Drug Service,Department of Pharmacy Services, Baltimore, Maryland

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

MSK Monmouth, Middletown, New Jersey

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York

Henry-Joyce Cancer Clinic, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Rambam Health Care Campus, Haifa, Not set

Division of Hematology Hadassah Medical Center - Ein Kerem, Jerusalem, Not set

Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Not set

The Chaim Sheba Medical Center, Ramat-Gan, Not set

Tel-Aviv Sourasky Medical Center, Tel Aviv, Not set

Conditions: Multiple Myeloma

Learn More ›

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

NCT05090566

Recruiting

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/28/2025

Locations: Banner Gateway Medical Center, Gilbert, Arizona +28 locations

Banner Gateway Medical Center, Gilbert, Arizona

Banner Gateway Medical Pavilion, Gilbert, Arizona

Banner MD Anderson Cancer Center, Gilbert, Arizona

University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas

Beverly Hills Cancer Center, Beverly Hills, California

Clinical Research Advisors, Encino, California

Clinical Research Advisors, Los Angeles, California

Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD, Los Angeles, California

Cedars Sinai Medical Center, Los Angeles, California

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI), Los Angeles, California

Clinical Research Advisors, Los Angeles, California

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida

Sylvester Comprehensive Cancer Center- Deerfield Beach, Deerfield Beach, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

UHealth Tower, Miami, Florida

UChicago Medicine - River East, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

UChicago Medicine at Ingalls - Flossmoor, Flossmoor, Illinois

UChicago Medicine Ingalls Memorial, Harvey, Illinois

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois

The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park, Illinois

UChicago Medicine at Ingalls - Tinley Park, Tinley Park, Illinois

OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility), Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta

The Ottawa Hospital - General Campus, Ottawa, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Multiple Myeloma

Learn More ›

Personalized Autologous Transplant for Multiple Myeloma

NCT04483206

Recruiting

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, term... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +1 locations

Conditions: Multiple Myeloma

Learn More ›

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

NCT06644625

Recruiting

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Gender:

ALL

Ages:

30 years and above

Trial Updated:

05/27/2025

Locations: Atrium Health Levine Cancer, Charlotte, North Carolina

Conditions: Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders

Learn More ›

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498

Recruiting

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded ind... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +59 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

USC/Norris Comprehensive Cancer Center, Los Angeles, California

UC San Diego Moores Cancer Center, San Diego, California

University of California San Francisco Medical Center, San Francisco, California

UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute, Atlanta, Georgia

IU Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Corewell Health - Lemmen-Holton Cancer Pavilion, Grand Rapids, Michigan

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

Novant Health Cancer Institute Hematology, Charlotte, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Oregon Health and Science University, Portland, Oregon

University of Tennessee Medical Center, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

The University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

LDS Hospital, Salt Lake City, Utah

Swedish Cancer Institute, Seattle, Washington

University of Washington Medical Center, Seattle, Washington

Royal Prince Alfred Hospital, Camperdown, New South Wales

Royal North Shore Hospital, St. Leonards, New South Wales

Royal Adelaide Hospital, Adelaide, South Australia

Epworth HealthCare, Richmond, Victoria

Sir Charles Gairdner Hospital, Nedlands, Western Australia

Ordensklinikum Linz GmbH Elisabethinen, Hamatologie mit Stammzelltransplantation, Hamostaseologie und medizinische Onkologie, Linz, Not set

University Hospital St. Poelten, Department of Internal Medicine I, St. Poelten, Not set

UZ Leuven, Flemish Brabant, Not set

UZ Gent, Gent Oost-Vlaanderen, Not set

CHU de Lille- Hopital Claude Huriez, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

CHU De Montpellier - Hopital Saint Eloi, Montpellier, Not set

Centre Hospitalier Universitaire de Nantes, Nantes, Not set

Hopital Saint Louis, Paris, Not set

Hopital Saint Antoine, Paris, Not set

Hôpital Lyon Sud, Pierre-Benite, Not set

Centre Hospitalier Universitaire de Poitiers, Poitiers, Not set

CHU de Rennes, Rennes, Not set

CHU de Toulouse. IUCT Oncopole, Toulouse, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI

IRCCS AOU di Bologna, Bologna, Not set

Hyogo Medical University Hospital, Hyogo, Not set

Japanese Red Cross Medical Center, Tokyo, Not set

University Medical Center Groningen, Groningen, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Not set

Hospital Universitario Ramon Y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Marqués de Valdecilla, Santander, Not set

Hospital Universitario Virgen del Rocio, Seville, Not set

Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Not set

University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Bristol, Not set

Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, Not set

University College London Hospital, London, Not set

Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle, Not set

Conditions: Multiple Myeloma

Learn More ›

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

NCT06910670

Recruiting

The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma

Learn More ›